Atsushi Okumura Selected Research

Interferons

1/2010

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsushi Okumura Research Topics

Disease

20	Infections 01/2021 - 09/2007
17	COVID-19 02/2022 - 01/2020
10	Pneumonia (Pneumonitis) 01/2022 - 08/2014
4	Vesicular Stomatitis 01/2022 - 09/2007
3	Virus Diseases (Viral Diseases) 01/2021 - 03/2008
2	Lung Diseases (Lung Disease) 02/2022 - 01/2022
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022 - 04/2020
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2022
2	Neoplasms (Cancer) 01/2016 - 01/2010
2	Shock 10/2015 - 01/2010
2	Ebola Hemorrhagic Fever 10/2015 - 01/2010
1	Hyperplasia 01/2022
1	Pulmonary Edema 01/2022
1	Asymptomatic Infections 12/2021
1	Crimean Hemorrhagic Fever 01/2021
1	Animal Disease Models 12/2020
1	Orthomyxoviridae Infections 02/2020
1	Coronavirus Infections 01/2020
1	Severe Acute Respiratory Syndrome 01/2020
1	Protein-Losing Enteropathies (Protein-Losing Enteropathy) 05/2018
1	Leukemia 01/2016
1	Human Influenza (Influenza) 10/2015
1	Lassa Fever (Fever, Lassa) 10/2015
1	Mesothelioma 01/2010
1	Malignant Mesothelioma 01/2010

Drug/Important Bio-Agent (IBA)

14	VaccinesIBA 01/2022 - 09/2007
8	Antiviral Agents (Antivirals)IBA 01/2022 - 03/2008
5	Pharmaceutical PreparationsIBA 01/2021 - 01/2020
5	Proteins (Proteins, Gene)FDA Link 01/2016 - 09/2007
4	molnupiravirIBA 02/2022 - 10/2020
4	remdesivirIBA 01/2022 - 01/2020
4	ChAdOx1 nCoV-19IBA 02/2021 - 05/2020
4	CytokinesIBA 10/2015 - 01/2010
2	NucleosidesIBA 02/2022 - 01/2022
2	Viral AntigensIBA 02/2022 - 01/2022
2	SARS-CoV-2 spike proteinIBA 01/2022 - 01/2021
2	Glycoproteins (Glycoprotein)IBA 01/2022 - 01/2021
2	Neutralizing AntibodiesIBA 01/2021 - 01/2021
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 12/2020 - 06/2020
2	Ribavirin (Virazole)FDA LinkGeneric 10/2015 - 10/2013
2	ChemokinesIBA 08/2014 - 10/2013
1	FibrinIBA 01/2022
1	RestonIBA 12/2021
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2021
1	A-Form DNA (A-DNA)IBA 01/2021
1	AntibodiesIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Pasteurella multocida toxinIBA 02/2020
1	ProdrugsIBA 01/2020
1	NucleotidesIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2016
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2016
1	EpitopesIBA 01/2016
1	Neuraminidase (Sialidase)IBA 01/2016
1	AntigensIBA 01/2016
1	favipiravirIBA 10/2015
1	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2010
1	eIF-2 Kinase (eIF 2 Kinase)IBA 01/2010
1	Interferon-betaIBA 01/2010
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2010
1	Messenger RNA (mRNA)IBA 01/2010
1	InterferonsIBA 01/2010
1	UbiquitinIBA 03/2008
1	UbiquitinsIBA 03/2008
1	Matrix-MIBA 09/2007

Therapy/Procedure

4	Therapeutics 04/2020 - 08/2014
1	Aftercare (After-Treatment) 05/2018
1	Immunotherapy 01/2016
1	Euthanasia (Mercy Killing) 08/2014
1	Oncolytic Virotherapy 01/2010